Business

Abivax Secures Funding for U.S. Launch

Updated 2026-07-10 10:25 UTC 1 source Neutral

French biotech Abivax secured a $920 million cash haul, enabling it to prepare for an independent U.S. launch without relying on a buyer, according to CEO statements.

Coverage timeline — 1 article

CNBC

Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC

Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.

2026-07-10 10:10 UTC